Bonaventura Eleonora, Alberti Luisella, Lucchi Simona, Cappelletti Laura, Fazzone Salvatore, Cattaneo Elisa, Bellini Matteo, Izzo Giana, Parazzini Cecilia, Bosetti Alessandra, Di Profio Elisabetta, Fiore Giulia, Ferrario Matilde, Mameli Chiara, Sangiorgio Arianna, Masnada Silvia, Zuccotti Gian Vincenzo, Veggiotti Pierangelo, Spaccini Luigina, Iascone Maria, Verduci Elvira, Cereda Cristina, Tonduti Davide
Child Neurology Unit, V. Buzzi Children's Hospital, Milan, Italy.
Center for Diagnosis and Treatment of Leukodystrophies and Genetic Leukoencephalopathies (COALA), V. Buzzi Children's Hospital, Milan, Italy.
Front Neurol. 2023 Jan 9;13:1072256. doi: 10.3389/fneur.2022.1072256. eCollection 2022.
X-linked adrenoleukodystrophy (X-ALD) is the most common inherited peroxisomal disorder caused by variants in the gene. The main phenotypes observed in men with X-ALD are primary adrenal insufficiency, adrenomyeloneuropathy, and cerebral ALD (cALD). Cerebral ALD consists of a demyelinating progressive cerebral white matter (WM) disease associated with rapid clinical decline and is fatal if left untreated. Hematopoietic stem cell transplantation is the standard treatment for cALD as it stabilizes WM degeneration when performed early in the disease. For this reason, early diagnosis is crucial, and several countries have already implemented their newborn screening programs (NBS) with the assessment of C26:0-lysophosphatidylcholine (C26:0-LPC) values as screening for X-ALD.
In June 2021, an Italian group in Lombardy launched a pilot study for the implementation of X-ALD in the Italian NBS program. A three-tiered approach was adopted, and it involved quantifying the values of C26:0-LPC and other metabolites in dried blood spots with FIA-MS/MS first, followed by the more specific ultra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) technique and, finally, the genetic confirmation focused NGS.
Genetically confirmed patients are set to undergo a follow-up protocol and are periodically evaluated to promptly start a specific treatment if and when the first signs of brain damage appear, as suggested by international guidelines. A specific disease monitoring protocol has been created based on literature data and personal direct experience.
The primary aim of this study was to develop a model able to improve the early diagnosis and subsequent follow-up and timely treatment of X-ALD.
The study was approved by the local ethics committee. The research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.
X连锁肾上腺脑白质营养不良(X-ALD)是由该基因变异引起的最常见的遗传性过氧化物酶体疾病。患有X-ALD的男性中观察到的主要表型为原发性肾上腺皮质功能不全、肾上腺脊髓神经病和脑型ALD(cALD)。脑型ALD是一种与临床快速衰退相关的脱髓鞘进行性脑白质(WM)疾病,若不治疗则会致命。造血干细胞移植是cALD的标准治疗方法,因为在疾病早期进行时它能稳定WM变性。因此,早期诊断至关重要,一些国家已经实施了新生儿筛查项目(NBS),通过评估C26:0-溶血磷脂酰胆碱(C26:0-LPC)值来筛查X-ALD。
2021年6月,意大利伦巴第的一个研究小组启动了一项在意大利NBS项目中实施X-ALD筛查的试点研究。采用了三级方法,首先用FIA-MS/MS定量干血斑中C26:0-LPC和其他代谢物的值,其次是更具特异性的超高效液相色谱-串联质谱(UHPLC-MS/MS)技术,最后是聚焦基因确认的二代测序(NGS)。
基因确诊的患者将接受随访方案,并定期进行评估,以便在出现脑损伤的首个迹象时(如国际指南所建议)及时开始特定治疗。基于文献数据和个人直接经验制定了特定的疾病监测方案。
本研究的主要目的是开发一种能够改善X-ALD早期诊断、后续随访及及时治疗的模型。
该研究获得了当地伦理委员会的批准。研究是在不存在任何可被视为潜在利益冲突的商业或财务关系的情况下进行的。